Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 11 recruiting now early-phase tilt small index

Esophageal Carcinoma: early-phase trial registry

11 of 18 indexed Esophageal Carcinoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #953 of 28,707 conditions by registered trial count.

18 US clinical trials · 11 currently recruiting · #953 of 28,707 conditions by registered trial count

Esophageal Carcinoma: 18 US clinical trials tracked, 11 recruiting.

Esophageal Carcinoma is the subject of 18 registered US clinical trials on ClinicalTrials.gov, 11 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 4 of these trials.

Enrollment posture brief

Registry condition esophageal-carcinoma

OPEN 11 | RECR 61% | LATE 0 | EARLY 9 | RANK #953 | SPON 4

Nearest open-share peer: Breast Cancer Metastatic (61% recruiting · 18 trials)

Esophageal Carcinoma (this)61%Arrhythmias, Cardiac27.8%Androgenetic Alopecia16.7%Anemia, Sickle Cell16.7%Acquired Immunodeficiency Sy5.6%
Open-enrollment share among volume-matched conditions near Esophageal Carcinoma

Esophageal Carcinoma lists 11 open slots (61% of 18 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Esophageal Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Esophageal Carcinoma is recruiting above its size-band peers.

    11 of 18 indexed trials (61.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Esophageal Carcinoma research.

    M.D. Anderson Cancer Center accounts for 4 of 18 trials (22.2%). 11 distinct sponsors appear on at least one study for this condition label.

  3. Most Esophageal Carcinoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 90 among the 18 trials that report a genuine target (sentinel values excluded). 11 of those (61.1%) plan for fewer than 100 participants.

  4. Esophageal Carcinoma research is mostly interventional.

    14 interventional and 4 observational studies make up this index (77.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 25

Open and recent trials

18 total, page 1 of 1

RECRUITING NA 24,000 participants

The Vanguard Study: Testing a New Way to Screen for Cancer

National Cancer Institute (NCI)

NCT06995898

RECRUITING 5,000 participants

Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy

M.D. Anderson Cancer Center

NCT00991094

RECRUITING 2,020 participants

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Guardant Health

NCT05059444

RECRUITING 1,600 participants

National Cancer Institute "Cancer Moonshot Biobank"

National Cancer Institute (NCI)

NCT04314401

RECRUITING NA 400 participants

Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers

M.D. Anderson Cancer Center

NCT03948100

RECRUITING Phase 2 90 participants

Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer

OHSU Knight Cancer Institute

NCT06067438

RECRUITING 60 participants

18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to Chemoradiation in Esophageal Cancer

M.D. Anderson Cancer Center

NCT06549413

RECRUITING Phase 2 50 participants

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

Mayo Clinic

NCT06265285

RECRUITING Phase 1 30 participants

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

Jonsson Comprehensive Cancer Center

NCT07118176

RECRUITING NA 20 participants

Impact of Prehabilitation in Oncology Via Exercise- Esophageal (IMPROVE-Esophageal)

University of Pittsburgh

NCT06872515

RECRUITING NA 20 participants

PET/CT Imaging to Evaluate Cardiac Radiation Damage in Patients With Lung or Esophageal Cancer, EUCLID Trial

Thomas Jefferson University

NCT05775939

ACTIVE NOT RECRUITING Phase 2 6,452 participants

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

NCT02465060

ACTIVE NOT RECRUITING NA 600 participants

Yoga Program for Improving the Quality of Life in Couples Coping With Cancer

M.D. Anderson Cancer Center

NCT04607590

ACTIVE NOT RECRUITING Phase 1 94 participants

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

National Cancer Institute (NCI)

NCT01366144

ACTIVE NOT RECRUITING Phase 2 40 participants

Induction Chemotherapy for Locally Advanced Esophageal Cancer

University of Rochester

NCT03110926

ACTIVE NOT RECRUITING Early Phase 1 29 participants

Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues

Jonsson Comprehensive Cancer Center

NCT04147494

COMPLETED Phase 2 61 participants

Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.

Memorial Sloan Kettering Cancer Center

NCT00590031

COMPLETED Phase 1 19 participants

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors

CRISPR Therapeutics

NCT05795595

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 5

Named interventions

Most-linked intervention names on Esophageal Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Questionnaire Administration Other
5 trials
Computed Tomography Procedure
4 trials
Positron Emission Tomography Procedure
3 trials
Gallium Ga 68 FAPi-46 Radiation
2 trials
Yoga Procedure
2 trials
Fludeoxyglucose F-18 Other
2 trials
Quality-of-Life Assessment Other
2 trials
Biospecimen Collection Procedure
2 trials

US sites by state

Facility locations filed on Esophageal Carcinoma trials. A trial with sites in several states counts in each.

California 7 trials
Texas 6 trials
New York 4 trials
Florida 4 trials
Pennsylvania 3 trials
Michigan 3 trials
Massachusetts 3 trials
Colorado 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Esophageal Carcinoma page

18 registered trials, 11 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Esophageal Carcinoma condition card totals 18 registered trials; most-linked intervention Questionnaire Administration; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.